Shares of Voyager Therapeutics skyrocketed after the company announced a collaborative deal to develop a gene therapy treatment for Parkinson’s disease with Neurocrine Biosciences.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
Biogen Inc. beat analysts’ estimates for fourth-quarter profit and revenue, buoyed by higher sales of the company’s top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.
CVS Health Corp.’s health insurer Aetna is working with Apple Inc. on a new health app for Apple Watches that uses an individual’s medical history to set personalized health goals.
SQI Diagnostics Inc. announced two new product launches within the imaware family of at-home tests by its partner, Microdrop.
Cerecor Inc. announced that the company moved its U.S. corporate offices to Rockville, Maryland after previously being based in Baltimore.
The one-time billionaire founder of Insys Therapeutics Inc. and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.